Trevi Therapeutics Gears Up for Key Investor Conferences
Trevi Therapeutics, Inc. (NASDAQ: TRVI) is a clinical-stage biopharmaceutical company known for its innovative work in developing Haduvio™, an investigational therapy aimed at treating chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). The company has announced its participation in several notable investor conferences taking place in February, marking an important opportunity to engage with investors and present its progress and future goals.
Details on the Upcoming Conferences
The following events are scheduled where Trevi’s senior management will be actively participating:
Piper Sandler Biopharma Mogul Summit
This summit will take place from February 2-4, 2025, offering a platform for thought leaders in the biopharma industry to connect. Lisa Delfini, the Chief Financial Officer of Trevi Therapeutics, will be representing the company. The summit provides an excellent opportunity for participants to discuss advancements in biopharmaceuticals and their potential impact on patient care.
Oppenheimer Healthcare 2025 Winter CEO & Investor Summit
Scheduled for February 3-6, 2025, this event in Vail, Colorado, will also feature Trevi at the forefront with CEO Jennifer Good taking the stage. The investor summit serves as a significant chance to highlight Trevi's innovative approaches and underscore its commitment to addressing the pressing healthcare needs of patients suffering from chronic cough.
Oppenheimer 35th Annual Healthcare Life Sciences Virtual Conference
This virtual conference is set for February 11-12, 2025. Trevi will hold a corporate presentation on February 11, from 9:20 to 9:50 am ET. Both Jennifer Good and Chief Development Officer James Cassella will present insights into the company's ongoing developments and strategic plans.
Understanding Chronic Cough
Chronic cough significantly impacts the quality of life for patients, particularly those suffering from IPF. It is noted that up to 85% of IPF patients experience chronic cough, which can lead to severe health complications and decreased quality of life. Trevi is well aware of these challenges, and Haduvio is under development to address this critical need.
Currently, there are no FDA-approved therapies for managing chronic cough in IPF patients, leaving many without effective treatment options. The health consequences of this can be staggering, with patients coughing excessively and facing social and psychological repercussions ranging from embarrassment to social isolation.
Addressing Refractory Chronic Cough
In addition to managing chronic cough in IPF, Trevi's focus extends to RCC, a condition affecting around 2-3 million adults in the U.S. The disruptions caused by this cough not only impact individuals physically but also lead to emotional and economic burdens, making it imperative for companies like Trevi to innovate solutions.
Haduvio's mechanism as a kappa agonist and mu antagonist (KAMA) is designed to provide relief by acting on both central and peripheral cough reflexes. This dual action targets the root of the cough, aiming for a much-needed solution for patients.
About Trevi Therapeutics, Inc.
The company continues to align its goals with improving patient care and fostering advancements in the field of biopharmaceuticals. Haduvio has not yet been evaluated by regulatory authorities, but the ongoing research and dedication shown by Trevi highlight their commitment to delivering effective therapies.
For those interested in staying up-to-date with Trevi Therapeutics, additional information can be found on the company’s official page, and they can be followed on popular social media networks, including X and LinkedIn. Engaging with the community will play a pivotal role as Trevi progresses towards its goals.
Investor and Media Contacts
For further inquiries, interested parties can contact Jonathan Carlson, located at Trevi Therapeutics, at (203) 654 3286. Media inquiries can be directed to Rosalia Scampoli at 914-815-1465.
Frequently Asked Questions
What is Haduvio and its purpose?
Haduvio is an investigational therapy aimed at treating chronic cough associated with idiopathic pulmonary fibrosis and refractory chronic cough.
Who will represent Trevi at the upcoming conferences?
Lisa Delfini, CFO, and Jennifer Good, CEO, will represent Trevi at various conferences in February.
Are there approved therapies for chronic cough?
Currently, there are no FDA-approved therapies for chronic cough in patients with idiopathic pulmonary fibrosis.
What role does chronic cough play in IPF?
Chronic cough significantly impacts patients' quality of life, potentially leading to severe complications and social isolation.
How can I stay updated with Trevi Therapeutics?
You can visit Trevi's official website and follow them on social media platforms like X and LinkedIn for the latest updates.
